Global Endometriosis Guidance Remains Uneven Across Regions and Populations
A scoping review of endometriosis guidelines has exposed a fragmented global field, where recommendations are abundant in some regions and sparse in others, and where the needs of adolescents, gender-diverse people, and patients in primary care are often underrepresented. The review drew on 47 guidelines published across multiple regions and languages, offering a rare view of how clinical advice for a common chronic inflammatory disease can diverge before a patient ever reaches the operating room or an expert clinic.
The pattern is hard to ignore. Most guidelines came from high-income settings, with Europe accounting for 15 of the 47 documents, or 32%. Africa accounted for just 2%, and the Eastern Mediterranean 4%, leaving large areas of the world with little formal guidance to shape diagnosis, referral, fertility counseling, and symptom management. In a disorder where diagnostic delay remains a major clinical burden, uneven guidance translates into uneven access to care.
Endometriosis is not a niche reproductive issue. It is a chronic inflammatory condition that can drive pain, infertility, missed work, repeated consultations, and escalating distress long before a definitive diagnosis is made. When guidance is concentrated in wealthier settings, the recommendations that reach front-line clinicians may assume imaging access, surgical expertise, laboratory infrastructure, or specialist referral pathways that do not exist elsewhere.
Evidence Grading, Inclusion, and the Reach of Care
Methodologic inconsistency emerged as a central problem. The included documents varied in how they graded evidence, and the review found substantial underrepresentation of groups whose perspectives should shape real-world guidance. Adolescents were underrepresented in 77% of guidelines, individuals with lived experience in 30%, and gender-diverse people in 19%. Primary care physicians, who often serve as the first point of contact for patients with pelvic pain, were explicitly considered in only 49% of guidelines.
Those omissions are not administrative details. They shape what a guideline can plausibly recommend and who is likely to benefit from it. Adolescents often present differently from adults, with symptoms that may be dismissed as routine menstrual pain. Gender-diverse people may face barriers in language, screening environments, and assumptions about reproductive anatomy. Primary care clinicians need guidance that is clear enough to support early suspicion, initial workup, pain control, and referral when appropriate.
One sentence captures the practical consequence: a guideline that excludes the front door of care will arrive too late for many patients.
The review also found inconsistent approaches to grading evidence, which complicates comparisons across documents and weakens confidence in the resulting recommendations. Without standardized methods, two guidelines can review the same evidence base and still produce different priorities for diagnosis or treatment. In a field already challenged by heterogeneity of symptoms and variable access to surgery, that methodological drift matters.
Diagnostic and Therapeutic Divergence at the Bedside
Several of the most clinically relevant disagreements centered on diagnosis and treatment pathways. Alignment across guidelines was limited for histological confirmation, biomarker use, aromatase inhibitors, repeat surgery, fertility care, non-medical interventions, and self-care strategies. These are not small differences in wording. They define whether clinicians are encouraged to confirm disease tissue surgically, rely on emerging biomarkers, repeat operative intervention, or broaden management beyond procedures and medication.
Histological confirmation remains especially consequential. In some settings, surgery and pathology remain the benchmark for diagnosis, while others may permit a more presumptive clinical approach. For patients, the difference influences time to diagnosis, the invasiveness of evaluation, and the likelihood of treatment beginning before disease becomes more entrenched. Biomarker recommendations are equally fraught: if evidence remains insufficient, guidelines may diverge between cautious skepticism and provisional endorsement, creating uncertainty for clinicians searching for less invasive diagnostic tools.
Aromatase inhibitors and repeat surgery illustrate how treatment philosophy can split across guidelines. One group of recommendations may favor escalation in refractory disease, while another urges restraint because of uncertain benefit, recurrence risk, or the limits of operative disease control. Fertility care adds another layer, since reproductive goals are central for many patients and cannot be separated from pain management or long-term planning. Non-medical interventions and self-care strategies, meanwhile, can be overlooked despite their role in daily symptom coping and patient autonomy.
Why Global Standardization Matters for Chronic Pelvic Pain
The review points toward a deeper systems problem: endometriosis care is being guided by documents that do not yet speak with a consistent global voice. In affluent settings, a patient may have access to multidisciplinary clinics, laparoscopic expertise, and fertility specialists. In lower-resource environments, the same patient may depend on generalists who need a concise, evidence-based framework for symptom recognition, initial medical therapy, and referral thresholds. A fragmented guideline ecosystem leaves those clinicians to improvise.
The consequences extend beyond diagnosis. If guidance does not explicitly include adolescents, gender-diverse people, and those first seen in primary care, then the path to care becomes narrower at the very moment it should be widening. If regional representation remains concentrated in Europe and other high-income settings, recommendations may reflect the realities of specialist-heavy health systems rather than the needs of patients who encounter long waits, limited imaging, or restricted surgical access.
The review’s findings also fit with the biology of endometriosis itself. A chronic inflammatory condition with variable pain expression and frequent overlap with infertility does not lend itself to one-size-fits-all management. Guidelines that fail to account for differing clinical presentations, care settings, and social realities risk being scientifically polished but operationally brittle.
What the Guideline Gaps Mean for Future Care Standards
The call emerging from the review is straightforward: a global normative guideline is needed, along with more standardized development methods and context-specific guidance that reflects the rights and needs of end-users. That would not mean erasing regional differences. It would mean establishing a more coherent core framework for diagnosis, treatment, and referral, then adapting it to local resources and populations rather than letting geography determine the quality of care by default.
A coordinated effort would also give greater weight to patient experience and to groups that have historically been left out of consensus building. Inclusive guideline development is not cosmetic. It affects whether a document addresses pain, fertility, adolescence, language, gender identity, and access to primary care in ways that can actually change clinical practice.
For now, the review leaves a concrete clinical message: endometriosis guidance remains uneven in reach, inconsistent in method, and incomplete in representation. The largest gaps are concentrated where patients are least likely to have easy access to specialist care, and the most clinically relevant disagreements remain unresolved in diagnosis, fertility, repeat surgery, and non-medical management. Those omissions will continue to shape care until the field settles on a shared framework that is both evidence-based and usable across very different health systems.